Abstract
The cell cycle is a complex event in which multiple regulator-proteins participate. The G1/S checkpoint of the cell cycle is controlled by pRb protein, which functions in its hypophosphorylated form as a negative regulator of growth. p27 (Kip1), a member of CIP/KIP family of cyclin inhibitory proteins, participates in inhibition of forming complexes that allow pRb to phosphorylate and lead the cell into mitosis. The expression of these important cell cycle regulator proteins was studied in a total of 96 non-Hodgkin's lymphoma (NHL) samples, which were classified according to the REAL classification. The expression of p27, pRb and the cell proliferation marker Ki-67 (MIB-1) was evaluated in lymphomas using immunohistochemistry. This study showed that there were coordinate changes in the expression of p27 and pRb in NHL. When compared to low-grade lymphomas, high-grade lymphomas showed significantly reduced expression of p27 and inversely pRb expression was increased (P < 0.001). Increase in expression of Ki-67 was parallel with pRb expression, and was mainly seen in cells that lacked p27 expression (P < 0.0001). This study suggests that changes in the control of the cell cycle closely relate to the pathobiology of NHL. © 2000 Cancer Research Campaign
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Catzavelos C, Bhattacharya N, Ung VC, Wilson JA, Roncari L, Sandhu C, Shaw P, Yeger H, Morava-Prozner I, Kapusta L, Franssen E, Pritchard KI and Slingerland JM (1997) Decreased levels of the cell-cycle inhibitor p27Kip1 protein: Prognostic implications in primary breast cancer. Nat Med 2: 227–230
Cinti C, Leoncini L, Nyongo A, Ferrari F, Lazzi S, Bellan C, Vatti R, Zamparelli A, Cevenini G, Tosi GM, Claudio PP, Maraldi NM, Tosi P and Giordano A (2000) Genetic alterations of the retinoblastoma-related gene RB2/p130 identify different pathogenetic mechanisms in and among Burkitt's lymphoma subtypes. Am J Pathol 156: 751–760
Clarke AR, Maandag ER, van Roon M, van der Luft NM, van der Valk M, Hooper ML, Berns A and te Riele H (1992) Requirement for a functional Rb-1 gene in murine development. Nature 359: 328–330
Geradts J, Andriko JW and Abbondanzo SL (1998) Loss of tumor suppressor gene expression in high-grade but not low-grade non-Hodgkin's lymphomas. Am J Clin Pathol 109: 669–674
Graña X and Reddy EP (1995) Cell cycle control in mammalian cells: role of cyclins, cyclin-dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs). Oncogene 11: 211–219
Hall M, Bates S and Peters G (1995) Evidence for different modes of action of cyclin-dependent kinase inhibitors: p15 and p16 bind to kinases, p21 and p27 bind to cyclins. Oncogene 11: 1581–1588
Harris NL, Jaffe ES, Stein H, Banks PM, Chan JKC, Cleary ML, Delso G, De Wolf-Peeters C, Falini B, Gatter KC, Grogan TM, Isaacson PG, Knowless DM, Mason DY, Muller-Hermelink HK, Pileri SA, Piris MA, Ralfkiaer E and Waroke RA (1994) A revised European–American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 84: 1361–1392
Hirama T and Koeffler HP (1995) Role of the cyclin-dependent kinase inhibitors in the development of cancer. Blood 86: 841–854
Hatta Y, Yamada Y, Tomonaga M and Koeffler HP (1997) Extensive analysis of the retinoblastoma gene in adult T cell leukemia/lymphoma. Leukemia 11: 984–989
Howard MO and Shipp MA (1998) The cellular and molecular heterogeneity of the aggressive non-Hodgkin's lymphomas. Curr Opin Oncol 10: 385–391
Korkolopoulou P, Angelopoulou MK, Kontopidou F, Tsenga A, Patsouris E, Thomas-Tsagli E, Kittas C and Pangalis GA (1998) Prognostic relevance of apoptotic cell death in non-Hodgkin's lymphomas: a multivariate survival analysis including Ki67 and p53 oncoprotein expression. Histopathology 33: 240–247
Lee EY, Chang CY, Hu N, Wang YC, Lai CC, Herrup K, Lee WH and Bradley A (1992) Mice deficient for Rb are nonviable and show defects in neurogenesis and haematopoiesis. Nature 359: 288–294
Leoncini L, Bellan C, Cossu A, Claudio PP, Lazzi S, Cinti C, Cevenini G, Megha T, Laurini L, Luzi P, Orcioni GF, Piccioli M, Pileri S, Giardino C, Tosi P and Giordano A (1999) Retinoblastoma-related p107 and pRb2/p130 proteins in malignant lymphomas: distinct mechanisms of cell growth control. Clin Cancer Res 5: 4065–4072
Mochen C, Giardini R, Costa A and Silvestrini R (1997) MiB1 and S-phase cell fraction predict survival in non-Hodgkin's lymphomas. Cell Prolif 1: 37–47
Non-Hodgkin's Lymphoma Classification Project (1997) A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Blood 89: 3909–3918
Polyak K, Kato J, Solomon MJ, Sherr CJ, Massague J, Roberts JM and Koff A (1994) p27Kip1, a Cyclin-Cdk inhibitor, links transforming growth factor-β and contact inhibition to cell cycle arrest. Genes Dev 8: 9–22
Porter PL, Malone KE, Heagerty PJ, Alexander GM, Gatti LA, Firpo EJ, Daling JR and Roberts JM (1997) Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat Med 3: 222–225
Quintanilla-Martinez L, Thiemblemont C, Fend F, Kumar S, Pinyol M, Campo E, Jaffe ES and Raffeld M (1998) Mantle cell lymphomas lack expression of p27Kip1, a cyclin-dependent kinase inhibitor. Am J Pathol 153: 175–182
Reynisdóttir I, Polyak K, Iavarone A and Massagué J (1995) Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-β. Genes Dev 9: 1831–1845
Rustgi AK, Dyson N and Bernards R (1991) Amino-terminal domains of c-myc and N-myc proteins mediate binding to the retinoblastoma gene product. Nature 352: 541–544
Sherr CJ (1996) Cancer cell cycles. Science 274: 1672–1677
Sherr CJ and Roberts JM (1995) Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev 9: 1149–1163
Stefanaki K, Tzardi M, Kouvidou C, Chaniotis V, Bolioti M, Vlychou M, Zois M, Kakolyris S, Delides G, Rontogianni D, Georgoulias V and Kanavaros P (1998) Expression of p53, p21, mdm2, Rb, bax and Ki-67 proteins in lymphomas of the mucosa-associated lymphoid (MALT) tissue. Anticancer Res 18: 2403–2408
Stranks G, Height SE, Mitchell P, Jadayel D, Yuille MA, De Lord C, Clutterbuck RD, Treleaven JG, Powles RL and Nacheva E (1995) Deletions and rearrangement of CDKN2 in lymphoid malignancy. Blood 35: 893–901
Uchida T, Kinoshita T, Murate T, Saito H and Hotta T (1998) CDKN2 (MTS1/p16INK4A) gene alterations in adult T-cell leukemia/lymphoma. Leuk Lymphoma 29: 27–35
Vrhovac R, Delmer A, Tang R, Marie JP, Zittoun R and Ajchenbaum-Cymbalista F (1998) Prognostic significance of the cell cycle inhibitor p27Kip1 in chronic B-cell lymphocytic leukemia. Blood 91: 4694–4700
Welch PJ and Wang JY (1993) A C-terminal protein-binding domain in the retinoblastoma protein regulates nuclear c-Abl tyrosine kinase in the cell cycle. Cell 75: 779–790
Xiao ZX, Chen J, Levine AJ, Modjtahedi N, Xing J, Sellers WR and Livingston DM (1995) Interaction between the retinoblastoma protein and the oncoprotein MDM2. Nature 375: 694–698
Yasui W, Kudo Y, Semba S, Yokozaki H and Tahara E (1997) Reduced expression of cyclin-dependent kinase inhibitor p27Kip1 is associated with advanced stage and invasiveness of gastric carcinomas. Jpn J Cancer Res 88: 625–629
Zheng T, Mayne ST, Boyle P, Holford TR, Liu WL and Flannery J (1992) Epidemiology of non-Hodgkin's lymphomas in Connecticut. Cancer 70: 840–849
Zucca E, Bertoni F, Roggero E and Cavalli F (1998) Management of rare forms of lymphoma. Curr Opin Oncol 10: 377–384
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Kiviniemi, M., Sauroja, I., Rajamäki, A. et al. Cell cycle regulators p27 and pRb in lymphomas – correlation with histology and proliferative activity. Br J Cancer 83, 1161–1167 (2000). https://doi.org/10.1054/bjoc.2000.1435
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2000.1435
Keywords
This article is cited by
-
pRb2/p130 protein expression and RBL2 mutation analysis in Burkitt lymphoma from Uganda
BMC Clinical Pathology (2009)
-
Proliferation-dependent expression and phosphorylation of pRB in B cell non-Hodgkin's lymphomas: dependence on RB1 copy number
Leukemia (2002)
-
Low Expression of p27 Protein Combined with Altered p53 and Rb/p16 Expression Status Is Associated with Increased Expression of Cyclin A and Cyclin B1 in Diffuse Large B-Cell Lymphomas
Modern Pathology (2001)